News

Mast cells in patients with systemic mastocytosis (SM) appear to express increased levels of galectin-3 and galectin-8.

A new review urges researchers to take a closer look at the bone marrow microenvironment when considering future treatment for SM.

A combination of quantitative and laboratory techniques may be used to improve the diagnosis of SM with flow cytometry, a recent study found.

New research highlights the link between clonal mast cell diseases like SM and severe systemic reactions to certain insect stings.

Osteoporosis affects 42% of people with indolent systemic mastocytosis (ISM) and is linked to spine and peripheral fractures.

A clinical trial is currently underway to determine the optimal dosage of a novel cancer drug in patients with ISM.

Vertebral fracture shape and distribution can be used to identify patients with a likely diagnosis of indolent SM.

A new treatment called bezuclastinib has shown promise in reducing symptoms of non-advanced systemic mastocytosis.

A first-of-its-kind study in Europe identified sources of disease burden as reported by patients with SM and their healthcare providers.

The use of diagnostic codes for mast cell disorders, such as systemic mastocytosis (SM), appears to be on the rise.